NCT00166946

Unknown

Effects of Arsenic on Keratinocytes in a Skin Equivalent Mod...

National Taiwan University Hospital Source

Compare

Other study identifiers

Sponsor study identifier

9361701179

Study Type

interventional

Reported enrollment (type unavailable)

20

Locations

1 country

Sites

2

Timeline

Study Start

June 2005

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

January 2008

Date type not reported

This date has not been verified as actual or estimated.

Brief Summary

We popose that arsenic-induced lymphocytes dysfunction plays an important role in biological mechanisms of arsenical Bowen's disease.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Reported enrollment (type unavailable): 20 participants
Study completion date: January 2008
Date type not reported
This date has not been verified as actual or estimated.
Listed locations: 1 countries · 2 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
June 2005
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 12, 2005
Actual (reported)
First Posted
September 14, 2005
Actual (reported)
Study Completion
January 2008
Date type not reported
This date has not been verified as actual or estimated.

Last Updated: December 21, 2005
Status Verified: November 2004
Last Update Submitted: December 20, 2005

Conditions

Bowen Disease

Outcome Measures

Primary Outcomes (1)

we collect foreskin from healthy adults

Interventions

foreskin from healthy adults for organotypic cultureProcedure

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age20 Years - 40 Years

Sexmale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Normal healthy adult -

You may not qualify if:

Sponsors & Collaborators

National Taiwan University Hospital
Otherlead

Study Sites (2)

National Taiwan University Hospital

Taipei, Taiwan, Province of China, 100, Taiwan

SUSPENDED

National Taiwan University Hospital

Taipei, 100, Taiwan

RECRUITING

Hsin-Su Yu, MD PHDCONTACT886-2-23562141 dermyu@ha.mc.ntu.edu.tw

MeSH Terms

Conditions

Bowen's Disease

Interventions

Microphysiological Systems

Condition Hierarchy (Ancestors)

Carcinoma, Squamous CellCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, Squamous Cell

Intervention Hierarchy (Ancestors)

Cell Culture Techniques, Three DimensionalCell Culture TechniquesCytological TechniquesClinical Laboratory Techniques

Study Officials

Hsin-Su Yu, MD PHD
National Taiwan Univesity Hospital, Dept. of Dermatology
STUDY DIRECTOR

Central Study Contacts

Hsin-Su Yu, MD PHD

CONTACT

886-2-23562141 dermyu@ha.mc.ntu.edu.tw

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: NONE
Purpose: ECT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER

Study Record Dates

First Submitted

September 12, 2005

First Posted

September 14, 2005

Study Start

June 2005

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

January 2008

Date type not reported

NCT01912976

Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease

Phase 1Completed

NCT03012009

Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial

Not ApplicableCompleted

NCT03167762

Photographing the Skin During Photodynamic Therapy

Not ApplicableCompleted

NCT01245972

Pilot Study of PDL to Treat BCC and SCCIS

Not ApplicableCompleted

NCT04844983

A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Phase 2Completed

NCT07809191

Hair Regrowth Following Partial Thickness Removal of SSCIS

Not ApplicableNot Yet Recruiting

systemic disease or with a history of exposure to arsenic-

Contact the study team to confirm eligibility.

Diagnostic Techniques and Procedures

Diagnosis

Investigative Techniques

Culture Techniques

In Vitro Techniques

Lab-On-A-Chip Devices

Micro-Electrical-Mechanical Systems

Electrical Equipment and Supplies

Equipment and Supplies

This date has not been verified as actual or estimated.

Last Updated

December 21, 2005

Record last verified: 2004-11

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00166946
Data provider: ClinicalTrials.gov
Source updated: 2005-12-21
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:17:27 UTC

Locations

TW(2)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations